Conditions: Healthy Volunteer
Allocation: RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 47
Healthy volunteers: yes

Brief summary:
The purpose of this study is to evaluate the safety and tolerability of single and multiple doses of LY2495655 administered subcutaneously and intravenously in Japanese subjects.

Detailed description:

Arms:
arm 1: Single 70 milligram (mg) dose LY2495655 administered intravenously (IV) arm 2: 17.5 mg of LY2495655 administered subcutaneously (SC) every 2 weeks for 8 weeks (total of 5 doses) arm 3: 140 mg of LY2495655 administered subcutaneously (SC) every 2 weeks for 8 weeks (total 5 doses) arm 4: 420 mg dose of LY2495655 administered subcutaneously (SC) every 2 weeks for 8 weeks (total 5 doses) arm 5: Single Placebo dose administered intravenously (IV) arm 6: Placebo dose administered subcutaneously (SC) every 2 weeks for 8 weeks (total of 5 doses)

Interventions: intervention 1: LY2495655 intervention 2: Placebo
Intervention descriptions: intervention 1: administered intravenously or subcutaneously intervention 2: administered intravenously or subcutaneously

Protocol document: